Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer
Juan Liu, … , Wenwei Hu, Zhaohui Feng
Juan Liu, … , Wenwei Hu, Zhaohui Feng
Published February 7, 2023
Citation Information: J Clin Invest. 2023;133(6):e164354. https://doi.org/10.1172/JCI164354.
View: Text | PDF
Research Article Cell biology Oncology

The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

  • Text
  • PDF
Abstract

The tumor suppressor TP53 is the most frequently mutated gene in human cancers. Mutant p53 (mutp53) proteins often accumulate to very high levels in human cancers to promote cancer progression through the gain-of-function (GOF) mechanism. Currently, the mechanism underlying mutp53 accumulation and GOF is incompletely understood. Here, we identified TRIM21 as a critical E3 ubiquitin ligase of mutp53 by screening for specific mutp53-interacting proteins. TRIM21 directly interacted with mutp53 but not WT p53, resulting in ubiquitination and degradation of mutp53 to suppress mutp53 GOF in tumorigenesis. TRIM21 deficiency in cancer cells promoted mutp53 accumulation and GOF in tumorigenesis. Compared with p53R172H knockin mice, which displayed mutp53 accumulation specifically in tumors but not normal tissues, TRIM21 deletion in p53R172H knockin mice resulted in mutp53 accumulation in normal tissues, an earlier tumor onset, and a shortened life span of mice. Furthermore, TRIM21 was frequently downregulated in some human cancers, including colorectal and breast cancers, and low TRIM21 expression was associated with poor prognosis in patients with cancers carrying mutp53. Our results revealed a critical mechanism underlying mutp53 accumulation in cancers and also uncovered an important tumor-suppressive function of TRIM21 and its mechanism in cancers carrying mutp53.

Authors

Juan Liu, Cen Zhang, Dandan Xu, Tianliang Zhang, Chun-Yuan Chang, Jianming Wang, Jie Liu, Lanjing Zhang, Bruce G. Haffty, Wei-Xing Zong, Wenwei Hu, Zhaohui Feng

×

Figure 4

TRIM21 inhibits mutp53 GOF in promoting anchorage-independent growth of cancer cells.

Options: View larger image (or click on image) Download as PowerPoint
TRIM21 inhibits mutp53 GOF in promoting anchorage-independent growth of ...
(A) TRIM21 KO enhanced anchorage-independent growth of SK-BR3 and HT29 cells, which was largely abolished by mutp53 KO. The control, TRIM21 KO, mutp53 KO, and TRIM21 + mutp53 double-KO cells were employed for anchorage-independent growth assays in soft agar. Left: Representative images of anchorage-independent growth of SK-BR3 cells. Right: Summary of relative cell colony numbers in soft agar. (B) Knockdown of endogenous TRIM21 by shRNA vectors enhanced anchorage-independent growth of LS1034 and HCC70 cells, which was largely abolished by mutp53 knockdown. The control, TRIM21 knockdown, mutp53 knockdown, and TRIM21 + mutp53 double-knockdown cells were employed for assays. (C) Ectopic TRIM21-Flag expression inhibited the anchorage-independent growth of SK-BR3 and HT29 cells, which was largely abolished by mutp53 KO. Control and mutp53 KO cells were transduced with control or TRIM21-Flag expression vectors for assays. (D) TRIM21 loss enhanced mutp53 GOF activity in promoting anchorage-independent growth of E1A/RasV12-transformed MEFs. The E1A/RasV12-transformed p53R172H/R172H, p53−/−, and p53+/+ MEFs with or without TRIM21 loss (TRIM21−/− or TRIM21+/+) were employed for assays. Left: Representative images of anchorage-independent growth of MEFs. Data are shown as the mean ± SD (n = 6). ANOVA followed by Dunnett’s test. #P < 0.05; *P < 0.01; ***P < 0.0001. Scale bars: 200 μm (A and D).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts